varlilumab
varlilumab
CAS: 1393344-72-3
Molecular Formula:
varlilumab - Names and Identifiers
| Name | varlilumab |
| Synonyms | varlilumab |
| CAS | 1393344-72-3 |
varlilumab - Introduction
varlilumab is a humanized monoclonal antibody under the trade name Avastin. Its main feature is the ability to specifically bind to and inhibit vascular endothelial growth factor (VEGF), thereby blocking the process of angiogenesis.
varlilumab is mainly used for the treatment of various malignant tumors, such as colorectal cancer, breast cancer, lung cancer, kidney cancer and ovarian cancer. Its mechanism of action is to inhibit the growth and spread of tumors by inhibiting the formation and supply of tumor blood vessels.
The preparation method of varlilumab is obtained by fusing humanized monoclonal antibodies with cell lines, and then large-scale production and purification by biotechnology methods.
Regarding safety information, varlilumab may have some side effects during clinical application. Common side effects include hypertension, hemostasis problems, allergic reactions, and proteinuria. Before using varlilumab, doctors will evaluate the patient's indications and risks for safety.
It is important to note that varlilumab is a prescription drug and must be prescribed and monitored by a professional physician on a patient-by-patient basis. During use, patients should pay close attention to their own reactions. If discomfort or serious side effects occur, they should consult and report to the doctor in time.
varlilumab is mainly used for the treatment of various malignant tumors, such as colorectal cancer, breast cancer, lung cancer, kidney cancer and ovarian cancer. Its mechanism of action is to inhibit the growth and spread of tumors by inhibiting the formation and supply of tumor blood vessels.
The preparation method of varlilumab is obtained by fusing humanized monoclonal antibodies with cell lines, and then large-scale production and purification by biotechnology methods.
Regarding safety information, varlilumab may have some side effects during clinical application. Common side effects include hypertension, hemostasis problems, allergic reactions, and proteinuria. Before using varlilumab, doctors will evaluate the patient's indications and risks for safety.
It is important to note that varlilumab is a prescription drug and must be prescribed and monitored by a professional physician on a patient-by-patient basis. During use, patients should pay close attention to their own reactions. If discomfort or serious side effects occur, they should consult and report to the doctor in time.
Last Update：2024-04-09 20:02:46
Supplier List
Spot supply
Product Name: Varlilumab Request for quotationCAS: 1393344-72-3
Tel: 400-968-2212
Email: 3623107365@qq.com
Mobile: 18916960931
QQ: 3623107365
Wechat: 18916960931
Spot supply
Product Name: Varlilumab Visit Supplier Webpage Request for quotationCAS: 1393344-72-3
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Multiple SpecificationsSpot supply
Product Name: Varlilumab (anti-CD27) Visit Supplier Webpage Request for quotationCAS: 1393344-72-3
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
Spot supply
Product Name: Varlilumab Request for quotationCAS: 1393344-72-3
Tel: 400-968-2212
Email: 3623107365@qq.com
Mobile: 18916960931
QQ: 3623107365
Wechat: 18916960931
Spot supply
Product Name: Varlilumab Visit Supplier Webpage Request for quotationCAS: 1393344-72-3
Tel: +86-400-900-4166
Email: product@acmec-e.com
Mobile: +86-18621343501
QQ: 2881950922
Wechat: 18621343501
WhatsApp: +86-18621343501
Multiple SpecificationsSpot supply
Product Name: Varlilumab (anti-CD27) Visit Supplier Webpage Request for quotationCAS: 1393344-72-3
Tel: 609-228-6898
Email: sales@medchemexpress.com
tech@medchemexpress.com
Mobile: 609-228-6898
View History